Fingerprint
Dive into the research topics of 'Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically